Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tonix Pharma ( (TNXP) ) just unveiled an announcement.
On December 9, 2025, Tonix Pharmaceuticals announced the appointment of Irina Ishak as General Counsel. Ms. Ishak, with over 25 years of experience in the life sciences industry, will lead the company’s legal, corporate governance, and compliance functions. Her appointment is expected to support Tonix’s commercialization efforts and strategic growth, particularly following the recent FDA approval of their fibromyalgia treatment, TONMYA.
The most recent analyst rating on (TNXP) stock is a Hold with a $19.50 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall score is primarily impacted by its financial challenges, including negative profitability and cash flow issues. Positive corporate events and short-term technical momentum provide some support, but the negative valuation metrics weigh heavily on the score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals is a fully-integrated biotechnology company that markets FDA-approved products, including TONMYA, a non-opioid analgesic for fibromyalgia, and treatments for acute migraine. The company focuses on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases, with a diverse pipeline of investigational drugs and biologics.
Average Trading Volume: 906,161
Technical Sentiment Signal: Sell
Current Market Cap: $231.3M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.